Professor Barnes is a translational neuropharmacologist within the College of Medical and Dental Sciences at the University of Birmingham and also the NHIR SRMRC, associated with the Queen Elizabeth Hospital, Birmingham. Professor Barnes’ research spans from cellular and molecular pharmacological mechanisms to assessing drug efficacy in clinical trial; with current funding over £8.5m from for example the MRC, NIHR, MoD and ‘big and SME’ pharma. Professor Barnes has published over 130 research papers giving rise to an h-index of 46 (including being the Principal Author of the most highly cited research paper ever from the University of Birmingham). Professor Barnes is Chairman of the International Union of Basic and Clinical Pharmacology (IUPHAR) Nomenclature Committee for 5-HT Receptors, a Councillor of the International Society for Serotonin Research and a Fellow of the British Pharmacological Society. He holds three editorships including Editor-in-Chief for the international journal Frontiers in Neuropharmacology and is an Honorary Professor at the University of Melbourne in Australia and the University of Siena in Italy.
Professor Barnes is also the Principal Founder and a Director of Celentyx Ltd (www.celentyx.com); a venture capital financed successful research and development pharmaceutical company established in 2007. In addition, research from Professor Barnes’ academic laboratory has also generated a number of revenue generating licensing deals with pharma and biotech for the University of Birmingham. Professor Barnes is called upon regularly at regional and national level to provide strategic and operational advice relevant to third stream ‘commercialisation’ activities.